RAP-219 hits primary endpoint in Phase 2 bipolar mania trial with statistically significant 3.1-point placebo-adjusted ...
Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.
A comprehensive review of drugs approved since 2018 reveals rapid innovation in schizophrenia, bipolar disorder and ...
“WELTRUZA offers the proven efficacy of olanzapine in an innovative long-acting subcutaneous injectable, helping to fill a major, long-standing gap in the schizophrenia treatment landscape,” said ...
FDA approves Teva's Weltruza, the first once-monthly subcutaneous olanzapine LAI for adult schizophrenia. Read what it means for patients and families.
The US FDA has approved Weltruza (olanzapine extended-release injectable suspension), a once-monthly subcutaneous formulation ...
Investigators examine drug concentrations, possible interactions and a 24-minute interruption in plasma exchange as they seek to establish the circumstances of the singer’s death ...
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key ...
Everyday Health on MSN
Bipolar medication and weight gain: Why it happens and how to manage it
Certain medications for bipolar disorder can cause unwanted weight gain. Find out what experts say you can do about it.
A1c can climb about 14 times faster in the first 90 days of antipsychotic treatment than with pre-therapy, marking a key ...
People starting antipsychotics need to closely track their weight and blood sugar for the first few months to avoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results